← Analyst Upside
AU · rank #14 · 2026-10-22
EOLS
NASDAQ · $486M (USD)
SignalBuy2.1strength 2.1 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.201 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.213 |
| Analyst upside Consensus target $15.00 | +102.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +21.62% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +66.4% |
| 52w high | $9.31 |
| Market cap (USD) | $486M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Evolus Inc is a commercial-stage aesthetic dermatology company marketing neurotoxin treatments (Jeuveau/Nuceiva) and hyaluronic acid dermal fillers (Evolysse/Estyme).
Rationale
Solid Q2 commercial performance featuring 21% revenue growth, a 52.6% earnings surprise, and raised FY2026 guidance validates the 100% upward EPS revision agreement and >102% target upside.
Material risks
- 1FDA regulatory enforcement following an October 2026 untitled letter regarding Jeuveau promotional claim violations could mandate costly corrective advertising or restrict marketing activities.
- 2Balance sheet leverage with $156.7 million in long-term debt against $45.2 million in cash and ongoing operating cash outflows leaves minimal buffer against intense competitive pricing pressure from Botox and Dysport.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed